CK2 inhibitors enhance the radiosensitivity of human non-small cell lung cancer cells through inhibition of Stat3 activation

Cancer Biotherapy and Radiopharmaceuticals

Volumn 26, Issue 3, 2011, Pages 381-388

  Lin, Yu Ching ^a,b,c   Hung, Ming Szu ^a,b,c   Lin, Chin Kuo ^a,c,d   Li, Jhy Ming ^a,e   Lee, Kuan Der ^a,d   Li, Ya Chin ^a   Chen, Miao Fen ^a   Chen, Jan Kan ^b   Yang, Cheng Ta ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^e NATIONAL CHIAYI UNIVERSITY   (Taiwan)

Author keywords

CK2; Irradiation; non small cell lung cancer; Stat3

Indexed keywords

4,5,6,7 TETRABROMO 1H BENZOTRIAZOLE; ANTINEOPLASTIC AGENT; CASEIN KINASE II; HEMATEIN; PROTEIN SERINE THREONINE KINASE INHIBITOR; RADIOSENSITIZING AGENT; RECOMBINANT EPIDERMAL GROWTH FACTOR; STAT3 PROTEIN; TETRABROMOCINNAMIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG MECHANISM; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; IRRADIATION; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY;

CARCINOMA, NON-SMALL-CELL LUNG; CASEIN KINASE II; CELL LINE, TUMOR; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOSE-RESPONSE RELATIONSHIP, RADIATION; ENZYME INHIBITORS; EPIDERMAL GROWTH FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; STAT3 TRANSCRIPTION FACTOR;

EID: 79960051228     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2010.0917     Document Type: Article

References (41)

1. Pinna LA. Protein kinase CK2. Int J Biochem Cell Biol 1997; 29:551.
2. Litchfield DW. Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J 2003; 369(Pt 1):1.
3. Ahmed K, Gerber DA, Cochet C. Joining the cell survival squad: An emerging role for protein kinase CK2. Trends Cell Biol 2002;12:226.
4. Meggio F, Pinna LA. One-thousand-and-one substrates of protein kinase CK2? FASEB J 2003;17:349.
5. Stalter G, Siemer S, Becht E, et al. Asymmetric expression of protein kinase CK2 subunits in human kidney tumors. Biochem Biophys Res Commun 1994;202:141.
6. Landesman-Bollag E, Romieu-Mourez R, Song DH, et al. Protein kinase CK2 in mammary gland tumorigenesis. Oncogene 2001;20:3247.
7. Daya-Makin M, Sanghera JS, Mogentale TL, et al. Activation of a tumor-associated protein kinase (p40TAK) and casein kinase 2 in human squamous cell carcinomas and adenocarcinomas of the lung. Cancer Res 1994;54:2262.
8. Faust RA, Tawfic S, Davis AT, et al. Antisense oligonucleotides against protein kinase CK2-alpha inhibit growth of squamous cell carcinoma of the head and neck in vitro. Head Neck 2000;22:341.
9. Yenice S, Davis AT, Goueli SA, et al. Nuclear casein kinase 2 (CK-2) activity in human normal, benign hyperplastic, and cancerous prostate. Prostate 1994;24:11.
10. Wang G, Unger G, Ahmad KA, et al. Downregulation of CK2 induces apoptosis in cancer cells-a potential approach to cancer therapy. Mol Cell Biochem 2005;274:77.
11. Di Maira G, Brustolon F, Bertacchini J, et al. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level. Oncogene 2007;26:6915.
12. Vilk G, Saulnier RB, St Pierre R, et al. Inducible expression of protein kinase CK2 in mammalian cells. Evidence for functional specialization of CK2 isoforms. J Biol Chem 1999; 274:14406.
13. Lebrin F, Chambaz EM, Bianchini L. A role for protein kinase CK2 in cell proliferation: Evidence using a kinaseinactive mutant of CK2 catalytic subunit alpha. Oncogene 2001;20:2010.
14. Pagano MA, Andrzejewska M, Ruzzene M, et al. Optimization of protein kinase CK2 inhibitors derived from 4,5,6,7- tetrabromobenzimidazole. J Med Chem 2004;47:6239.
15. Duncan JS, Litchfield DW. Too much of a good thing: The role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008;1784:33.
16. Pagano MA, Cesaro L, Meggio F, et al. Protein kinase CK2: A newcomer in the druggable kinome. Biochem Soc Trans 2006;34(Pt 6):1303.
17. Pagano MA, Poletto G, Di Maira G, et al. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem 2007;8:129.
18. Haura EB, Zheng Z, Song L, et al. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin Cancer Res 2005;11:8288.
19. Mukohara T, Kudoh S, Yamauchi S, et al. Expression of epidermal growth factor receptor (EGFR) and downstreamactivated peptides in surgically excised non-small-cell lung cancer (NSCLC). Lung Cancer 2003;41:123.
20. Seki Y, Suzuki N, Imaizumi M, et al. STAT3 and MAPK in human lung cancer tissues and suppression of oncogenic growth by JAB and dominant negative STAT3. Int J Oncol 2004;24:931.
21. Alvarez JV, Greulich H, Sellers WR, et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res 2006;66: 3162.
22. Yeh HH, Lai WW, Chen HH, et al. Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion. Oncogene 2006;25:4300.
23. Gao SP, Mark KG, Leslie K, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 2007; 117:3846.
24. Piazza FA, Ruzzene M, Gurrieri C, et al. Multiple myeloma cell survival relies on high activity of protein kinase CK2. Blood 2006;108:1698.
25. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm-general principles. Nat Clin Pract Oncol 2007;4:86.
26. Kvols LK. Radiation sensitizers: A selective review of molecules targeting DNA and non-DNA targets. J Nucl Med 2005;46 Suppl 1:187S.
27. Liebmann J, Cook JA, Fisher J, et al. In vitro studies of taxol as a radiation sensitizer in human tumor cells. J Natl Cancer Inst 1994;86:441.
28. Fukuoka K, Arioka H, Iwamoto Y, et al. Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 2001; 34:451.
29. Fukada T, Hibi M, Yamanaka Y, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: Involvement of STAT3 in anti-apoptosis. Immunity 1996;5:449.
30. Kim KW, Mutter RW, Cao C, et al. Inhibition of signal transducer and activator of transcription 3 activity results in down-regulation of Survivin following irradiation. Mol Cancer Ther 2006;5:2659.
31. Sitko JC, Yeh B, Kim M, et al. SOCS3 regulates p21 expression and cell cycle arrest in response to DNA damage. Cell Signal 2008;20:2221.
32. Otero DC, Poli V, David M, et al. Cutting edge: Inherent and acquired resistance to radiation-induced apoptosis in B cells: a pivotal role for STAT3. J Immunol 2006;177:6593.
33. Calvin DP, Nam S, Buettner R, et al. Inhibition of STAT3 activity with STAT3 antisense oligonucleotide (STAT3-ASO) enhances radiation-induced apoptosis in DU145 prostate cancer cells. Int J Radiat Oncol Biol Phys 2003;57:S297.
34. Pepperkok R, Lorenz P, Ansorge W, et al. Casein kinase II is required for transition of G0/G1, early G1, and G1/S phases of the cell cycle. J Biol Chem 1994;269:6986.
35. Hung MS, Xu Z, Lin YC, et al. Identification of hematein as a novel inhibitor of protein kinase CK2 from a natural product library. BMC Cancer 2009;9:135.
36. Sordella R, Bell DW, Haber DA, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 2004;305:1163.
37. Sato M, Vaughan MB, Girard L, et al. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res 2006;66:2116.
38. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295.
39. Huang C, Li J, Ding M, et al. UV Induces phosphorylation of protein kinase B (Akt) at Ser-473 and Thr-308 in mouse epidermal Cl 41 cells through hydrogen peroxide. J Biol Chem 2001;276:40234.
40. Brognard J, Clark AS, Ni Y, et al. Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res 2001;61:3986.
41. Kim JS, Eom JI, Cheong JW, et al. Protein kinase CK2alpha as an unfavorable prognostic marker and novel therapeutic target in acute myeloid leukemia. Clin Cancer Res 2007;13:1019.